Trial Profile
Phase I Study of Combination of Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Sep 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Cancer; Gastric cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Small cell lung cancer
- Focus Adverse reactions
- 31 Aug 2022 Status changed from active, no longer recruiting to completed.
- 26 Apr 2022 Planned End Date changed from 1 Apr 2021 to 1 Apr 2023.
- 26 Apr 2022 Planned primary completion date changed from 1 Apr 2020 to 1 Apr 2023.